Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.68 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.67 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.67 |
| ▸ | EGFR | P00533 | 1/20 | 0.67 |
| ▸ | ESR1 | P03372 | 1/20 | 0.67 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.67 |
| ▸ | FYN | P06241 | 1/20 | 0.67 |
| ▸ | PGR | P06401 | 1/20 | 0.67 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.67 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.67 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.67 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.67 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5002513 | 1.00 | CYSLTR1 (0.68) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL5002515 | 1.00 | CYSLTR1 (0.68) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL13042615 | 0.94 | CYSLTR1 (0.68) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL10054292 | 0.93 | CYSLTR1 (0.79) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL12724464 | 0.93 | CYSLTR1 (0.79) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL1401162 | 0.93 | CYSLTR1 (0.79) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL3265520 | 0.93 | CYSLTR1 (0.79) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL13424212 | 0.92 | CYSLTR1 (0.64) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL12596761 | 0.92 | CYSLTR1 (0.64) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL13302229 | 0.89 | CYSLTR1 (0.61) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948611-B1 | Process for the preparation of a leukotriene antagonist and intermediates thereof | ESTEVE QUIMICA SA (ES) | 2012-05-23 | — | — | EP | disclosed |
| US-20080306270-A1 | Process for the Preparation of a Leukotriene Antagonist and Intermediates Thereof | Esteve Química, S.A. (ES) | 2008-12-11 | — | — | US | disclosed |
| EP-1948611-A2 | PROCESS FOR THE PREPARATION OF A LEUKOTRIENE ANTAGONIST AND INTERMEDIATES THEREOF | ESTEVE QUIMICA, S.A. (ES) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007051828-A2 | PROCESS FOR THE PREPARATION OF A LEUKOTRIENE ANTAGONIST AND INTERMEDIATES THEREOF | ESTEVE QUÍMICA, S. A. (ES) | 2007-05-10 | — | — | WO | disclosed |
| EP-1783117-A1 | Process for the preparation of a leukotriene antagonist and intermediates thereof | ESTEVE QUIMICA, S.A. (ES) | 2007-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306270-A1 | Process for the Preparation of a Leukotriene Antagonist and Intermediates Thereof | LTC4S, LTB4R, CYSLTR1 | CYSLTR1 3/4885CYP2C8 110/4885CYSLTR2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.